Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors

Next Previous
Trial Profile

A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sacituzumab govitecan (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Endometrial cancer; Head and neck cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Tropics-03
  • Sponsors Gilead Sciences; Immunomedics

Most Recent Events

  • 03 Mar 2025 Planned End Date changed from 1 Mar 2025 to 1 Sep 2025.
  • 17 Dec 2024 According to Gilead Sciences media release, based on result form this trial, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy.
  • 05 Sep 2024 According to Gilead Sciences media release, company will present updated results from the global Phase 2 TROPiCS-03 ES-SCLC Cohort during the IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, taking place Sept. 7-10, 2024 in San Diego, Calif.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top